1 ase (ILD) in a large cohort of patients with anti-Jo-1 antibodies.

2 0 (DNA topoisomerase I), anticentromere, and anti-Jo-1 antibodies.

3 dy revealed a modest correlation between the anti-Jo-1 antibody level and the serum creatine kinase (

4            Further, there was a reduction in anti-Jo-1 antibody levels and a partial recovery of IgA

5 eries have examined the relationship between anti-Jo-1 antibody levels and myositis disease activity,

6 s were used to identify associations between anti-Jo-1 antibody levels and organ-specific disease act

7 ematically reexamine the association between anti-Jo-1 antibody levels and various disease manifestat

8 ients with idiopathic inflammatory myopathy, anti-Jo-1 antibody levels correlated modestly with muscl

9 analyses of 11 patients with serial samples, anti-Jo-1 antibody levels correlated significantly with

10 er longitudinal subset of patients that link anti-Jo-1 antibody levels to muscle, joint, lung, and gl

11                                        Serum anti-Jo-1 antibody levels were quantified using 2 indepe

12 ests, and peripheral blood quantification of anti-Jo-1 antibody levels, lymphocyte subsets, immunoglo

13 atistically significant associations between anti-Jo-1 antibody-positive ILD and elevated serum level

14 trated disease-specific associations between anti-Jo-1 antibody-positive ILD and serum levels of CRP

15 to assess the serum proteins associated with anti-Jo-1 antibody-positive ILD.

16 g studies determined the existence of ILD in anti-Jo-1 antibody-positive individuals whose data were

17                                 Among the 90 anti-Jo-1 antibody-positive individuals with sufficient

18                      In this large cohort of anti-Jo-1 antibody-positive individuals, the incidence o

19 oss-sectional assessment of 81 patients with anti-Jo-1 antibody revealed a modest correlation between